Physician profile
Dick Chuang
NPI 1588752349
$7,279.58
in general payments reported to CMS, 2019-2025
44 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $989 · 2022: $1,630 · 2023: $1,325 · 2024: $1,489 · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,660.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $789.01 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $758.29 | 2021-2025 | |
| Novo Nordisk INC | $748.42 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $746.68 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $537.85 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Glaxosmithkline, LLC. | $491.16 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Almatica Pharma LLC | $286.35 | 2021-2024 | Loreev Xr, Gralise, Teriparatide |
| Nestle Healthcare Nutrition INC. | $226.56 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.53 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $201.25 | 2024-2025 | Breztri |
| Abbott Laboratories | $197.85 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sumitomo Pharma America, INC. | $187.22 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.78 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.21 | 2021-2025 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $129.67 | 2021-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dick Chuang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.